EGFR and colorectal cancer: Preliminary results showed that more than 50 patients were treated with adagrasib in combination with either pembrolizumab (a PD-1 inhibitor) for NSCLC, cetuximab (an anti-EGFR antibody) for colorectal cancer, or TNO-155 (an SHP-2 inhibitor) for NSCLC or colorectal cancer.